What was studied?
An unknown preparation submitted to a laboratory was examined using liquid chromatography and high-resolution tandem mass spectrometry. The investigators interpreted fragmentation data to propose an amino-acid sequence and a terminal modification.
What did the researchers report?
They identified a 29-amino-acid peptide with a C-terminal amide and discussed its consistency with material marketed as CJC-1295. The paper illustrates how analytical identity can be investigated independently of marketing terminology.
What are the limits?
This is a single analytical investigation, not a clinical trial or a survey of all products. A proposed sequence does not establish purity, sterility, net content or equivalence to an albumin-binding clinical analogue. The original methods and reference materials matter when interpreting identity claims.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.